Table 3.
Event (n) | PEDF Tertile | Initial Model HR (95% CI)* |
Second Model HR (95% CI)† |
---|---|---|---|
MI (n=46) |
Lowest | 1.00 | 1.00 |
Second | 0.58 (0.26, 1.28) | 0.56 (0.24, 1.30) | |
Third | 1.06 (0.56, 2.02) | 1.03 (0.48, 2.19) | |
MI, procedure or inoperable disease (n=104) |
Lowest | 1.00 | 1.00 |
Second | 0.73 (0.44, 1.21) | 0.70 (0.41, 1.17) | |
Third | 1.03 (0.66, 1.60) | 0.91 (0.54, 1.51) | |
MI or CV Death (n=67) |
Lowest | 1.00 | 1.00 |
Second | 0.72 (0.38, 1.36) | 0.58 (0.29, 1.14) | |
Third | 1.26 (0.73, 2.18) | 1.02 (0.55, 1.89) | |
Composite Endpoint (n=165) |
Lowest | 1.00 | 1.00 |
Second | 1.02 (0.69, 1.50) | 0.97 (0.64, 1.46) | |
Third | 1.21 (0.84, 1.74) | 1.01 (0.66, 1.55) | |
All Death (n=66) |
Lowest | 1.00 | 1.00 |
Second | 2.03 (1.06, 3.88) | 1.65 (0.82, 3.31) | |
Third | 2.00 (1.03, 3.89) | 1.40 (0.68, 2.88) |
Adjusted for age, minority status, treatment arm and prior cardiovascular event. Moreover, utilization of left-truncation in our marginal multivariate Cox proportional hazard models enables us to account for age at VADT baseline and at first PEDF measurement. These models also allow us to include PEDF measurements at two time points for a single individual when data is available.
Additionally adjusted for smoking status and diabetes duration at date of randomization as well as systolic blood pressure, HDL, use of ACE inhibitors and statins at time of biomarker measurement.